SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 4,533 shares, a growth of 1,237.2% from the April 30th total of 339 shares. Based on an average daily trading volume, of 32,028 shares, the short-interest ratio is presently 0.1 days.
SAB Biotherapeutics Stock Performance
NASDAQ:SABSW remained flat at $0.02 during midday trading on Wednesday. The company had a trading volume of 25 shares, compared to its average volume of 21,859. The firm has a 50-day moving average price of $0.02 and a two-hundred day moving average price of $0.03. SAB Biotherapeutics has a one year low of $0.02 and a one year high of $0.18.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
See Also
- Five stocks we like better than SAB Biotherapeutics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
